PHILADELPHIA—“At age 12, I was diagnosed with psoriasis (PsO), followed by a diagnosis of psoriatic arthritis (PsA) at age 30,” said Ashley Krivohlavek of Oklahoma City in a poster presentation at ACR Convergence 2022. “I’m now 38.” Ms. Krivohlavek’s Story In 2020, I had been on an infused biologic for 18 months, but my…
After examining study data from pediatric patients with both psoriasis and psoriatic arthritis (PsA), the FDA approved ustekinumab as a treatment for patients aged 6–17 years old with PsA.
The National Psoriasis Foundation estimates that more than 8 million people in the U.S. suffer from psoriasis and that approximately 30% of those individuals develop psoriatic arthritis (PsA).1 Given these statistics, roughly 2.4 million people in the country are likely affected by PsA. Moreover, patients with this systemic condition carry a higher-than-average burden of cardiometabolic…
Ana-Maria Orbai, MD, MHS, addressed the latest research into psoriatic arthritis (PsA), including a comprehensive overview of the latest FDA-approved treatments and their implications for clinical practice.
Research has demonstrated that deucravacitinib is significantly more efficacious than placebo for achieving minimal disease activity in patients with active PsA after 16 weeks of treatment.
This EULAR 2022 session emphasized the importance of recognizing the axial manifestations of psoriatic arthritis and treating these symptoms accordingly.
For best safety and efficacy outcomes, trials in psoriatic arthritis should use active comparators and stricter remission criteria, with outcome measures that are important to patients.
In the E.U., secukinumab is edging closer to approval for use in pediatric patients with juvenile idiopathic arthritis (JIA), specifically those with enthesitis-related arthritis (ERA) and juvenile psoriatic arthritis (PsA). In May, the Committee for Medicinal Products for Human Use of the European Medicines Agency issued a positive opinion on expanding its indications.
HLA-B27 may be a phenotypic expression of axial spondyloarthritis (SpA), according to a large international study. The study found patients with axial SpA who were positive for HLA-B27 had more severe radiographic damage than those who were negative for HLA-B27, and three quarters of study patients with ankylosis spondyloarthritis were HLA-B27 positive.
With many new agents designed to treat PsA, rheumatologists and patients have options. Schwartzman et al. examined the real-world use of different treatments and ranked patient medication preferences.